- Home
- / Dongkoo Bio&Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Dongkoo Bio&Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩5.6 K
2024-10-29
Market Capitalization
₩149.6 B
2024-10-29
Revenue
₩249.3 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 104.8B | 125.2B | 139.2B | 155.1B | 195.0B | 215.7B | 249.3B |
| Cost of goods sold | 35.2B | 42.8B | 45.7B | 48.8B | 59.0B | 78.3B | 90.9B |
| Gross profit | 70.2B | 84.8B | 94.2B | 110.0B | 136.0B | 137.4B | 158.6B |
| Gross profit margin, % | 67.7% | 67.7% | 70.9% | 69.8% | 63.7% | 63.6% | |
| Operating expense total | 61.7B | 72.9B | 81.4B | 93.1B | 113.8B | 116.7B | 138.4B |
| Depreciation and amortization | 2.3B | 3.1B | 4.5B | 5.1B | 5.2B | 6.0B | 7.9B |
| EBITDA | 8.3B | 21.7B | 13.6B | 15.1B | 22.3B | 20.1B | 7.1B |
| EBITDA margin, % | 17.3% | 9.7% | 9.7% | 11.5% | 9.3% | 2.8% | |
| EBIT | 5.6B | 18.6B | 8.8B | 10.0B | 16.8B | 13.8B | (2.1B) |
| EBIT margin, % | 14.8% | 6.3% | 6.4% | 8.6% | 6.4% | -0.8% | |
| Interest income | 201.7M | 184.0M | 77.6M | 50.9M | 179.4M | 310.5M | 224.4M |
| Interest expense | 363.9M | 398.7M | 430.8M | 415.6M | 1.0B | 1.8B | 2.9B |
| Pre tax profit | 5.3B | 18.2B | 10.3B | 11.3B | 7.9B | 14.7B | 3.8B |
| Income tax expense | 751.2M | 3.1B | 1.2B | 1.5B | 1.3B | 2.9B | 1.8B |
| Net Income | 4.6B | 15.1B | 9.1B | 9.9B | 6.6B | 11.8B | 2.0B |